Impact of Netrin-1 in the Pathophysiology of Placenta Accreta Spectrum

September 2, 2023 updated by: Hanaa Mohammed Mohammed Sayed, Assiut University

The main goal of this study the possible involvement of netrin-1 into the pathophysiology of placenta accrete spectrum.

To delineate the role of netrin-1, neogenin - zeb1 signaling pathway in mechanism of morbidly adherent placenta.

Study Overview

Status

Completed

Conditions

Detailed Description

The main goal of this study is:

  • To shed light on the possible involvement of netrin-1 into the pathophysiology of placenta accrete spectrum.
  • To study the role of netrin-1 in Epithelial to mesenchymal transition as a possible pathophysiological mechanism of placenta accrete spectrum.
  • To delineate the role of netrin-1, neogenin - zeb1 signaling pathway in the progression of invasion of placenta accrete spectrum.

Study Type

Observational

Enrollment (Actual)

50

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: hanaa mohammed mohammed sayed, assistant lecturer
  • Phone Number: 01016113232
  • Email: hanaa.dwak@yahoo.com

Study Contact Backup

Study Locations

  • Egypt
      • Assiut, Egypt
        • Hanaa Mohammed Mohammed Sayed

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 40 years (Adult)

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

  1. Full history taking including currant age, age of marriage, parity, history of abortion , history of dilation and endometrial curettage(D&C), number of previous caesarian section, history of uterine congenital anomaly, postpartum endometritis, hysteroscopic surgery, previous abnormal placentation, and similar condition in the family.
  2. Estimation of body mass index (BMI). 3- placental tissue obtained after delivery for immunohistochemistry and tissue homogenate analysis

Description

Inclusion Criteria:

  • ages between 20 to 40 years will be included.
  • Gestational age: between 34 to 38 weeks.
  • History of previous cesarean sections.

  • Ultrasonographic findings suggestive PAS according to Jauniaux et al. (2018) :

    • Loss of the retro-placental clear zone.
    • Thinning of myometrium.
    • Abnormal placental lacunae.
    • Bladder wall interruption.
    • Placental bulge.
    • Exophytic placental mass.

  • Doppler findings suggestive PAS according to Jauniaux et al. (2018):

    • Subplacental hypervascularity.
    • Uterovesical hypervascularity/bridging vessels.
    • Vascular lacunae with turbulent flow/feeder vessels.

Exclusion Criteria:

Fundal and middle anterior or posterior placenta.

• Pregnancy associated with morbid conditions as: hypertension, diabetes mellitus, autoimmune disease, cardiac disease, renal disease, and endocrinal disease.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
group A
group A : placental tissue of 30 patients with placenta accreta
group B
group B : placental tissue of 30 normal pregnancy as a control group

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
impact of netrin-1 in the pathophysiology of placenta accreta spectrum
Time Frame: baseline
Estimation of local placental netrin-1 protein expression by immunohistochemistry , Estimation of local placental expression of neognin by immunohistochemistry. Estimation of local placental expression of Zeb-1 by immunohistochemistry
baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Assiut University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 1, 2020

Primary Completion (Actual)

November 1, 2021

Study Completion (Actual)

December 1, 2021

Study Registration Dates

First Submitted

November 9, 2020

First Submitted That Met QC Criteria

November 9, 2020

First Posted (Actual)

November 13, 2020

Study Record Updates

Last Update Posted (Actual)

September 7, 2023

Last Update Submitted That Met QC Criteria

September 2, 2023

Last Verified

September 1, 2023

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • netrin-1 in placenta accreta

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pathophysiology of Placenta Accreta

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Qatar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe